<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688803</url>
  </required_header>
  <id_info>
    <org_study_id>20160078-01H</org_study_id>
    <nct_id>NCT02688803</nct_id>
  </id_info>
  <brief_title>Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)</brief_title>
  <acronym>OTT15-04</acronym>
  <official_title>Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) OTT 15-04</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have &lt;1%&#xD;
      expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over&#xD;
      express HER2.&#xD;
&#xD;
      TNBC is diagnosed in 15-20% of breast cancer cases and tends to occur in younger women and&#xD;
      have biologically more aggressive high grade disease. Clinically, patients with TNBC have a&#xD;
      poorer prognosis compared to patients diagnosed with other breast cancer subtypes. Because of&#xD;
      the aggressive phenotype and due to observations that systemic chemotherapy offers&#xD;
      significantly higher benefit in ER negative disease, current treatment guidelines from&#xD;
      provincial and other organizations recommend that patients receive adjuvant systemic&#xD;
      chemotherapy for any TNBC greater than 0.5 cm in greatest diameter or node positive&#xD;
      independent of primary tumor size.&#xD;
&#xD;
      Currently, there is no world-wide standard recommended chemotherapy regimen for the&#xD;
      management of TNBC in the neoadjuvant/adjuvant setting, with treatments varying from region&#xD;
      and institution.&#xD;
&#xD;
      As physicians do not know what the &quot;best&quot; treatment for patients is, genuine uncertainty&#xD;
      (&quot;clinical equipoise&quot;) exists. Physicians will choose between different &quot;standards&quot; in their&#xD;
      personal practice, using idiosyncratic decision making processes, without the physician or&#xD;
      the patient knowing the optimal option. This is not good for patients, physicians and society&#xD;
      as a whole. Determining the optimal treatment remains an important medical issue for&#xD;
      patients, physicians and society. This study will survey opinions on a novel method to allow&#xD;
      comparisons of established standard of care prophylactic treatment using the &quot;integrated&#xD;
      consent model&quot; as part of a pragmatic clinical trial and attempt to compare head to head&#xD;
      standard chemotherapy regimens in patients with TNBC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who receive chemotherapy in the neoadjuvant/adjuvant setting for TNBC</measure>
    <time_frame>One year</time_frame>
    <description>Percentage of patients who receive chemotherapy in the neoadjuvant/adjuvant setting for TNBC compared to the number of participants who after being approached subsequently agree to randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant satisfaction</measure>
    <time_frame>One year</time_frame>
    <description>Participant satisfaction survey. Overall participant satisfaction will be determined using the participant survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who complete study treatment</measure>
    <time_frame>One hour</time_frame>
    <description>Percentage of participants who complete study treatment compared to the percentage who discontinue their treatment while on study (compliance) will be calculated using the sites chemotherapy treatment records and data from New Patient Registration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>One year</time_frame>
    <description>Rate of adverse effects requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment delays</measure>
    <time_frame>One year</time_frame>
    <description>Rate of adverse effects requiring treatment delays</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dose dense AC-P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose dense AC-P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose dense AC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FEC-D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose dense AC-P</intervention_name>
    <description>(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)</description>
    <arm_group_label>Dose dense AC-P</arm_group_label>
    <other_name>doxorubicin</other_name>
    <other_name>cyclophosphamide</other_name>
    <other_name>paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose dense AC</intervention_name>
    <description>Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)</description>
    <arm_group_label>Dose dense AC</arm_group_label>
    <other_name>doxorubicin</other_name>
    <other_name>cyclophosphamide</other_name>
    <other_name>paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FEC-D</intervention_name>
    <description>FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)</description>
    <arm_group_label>FEC-D</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>cyclophosphamide</other_name>
    <other_name>docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed primary TNBC breast cancer&#xD;
&#xD;
          -  Planned for chemotherapy&#xD;
&#xD;
          -  â‰¥18 years of age&#xD;
&#xD;
          -  Able to provide verbal consent&#xD;
&#xD;
          -  Willing to complete a survey&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Contraindication to one or more of the chemotherapy agents being evaluated in the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Hilton, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2 Negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

